Версия сайта для людей с нарушением зрения
    шрифт
только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Обычная версия
Раздел 3 / 4
Страница 1 / 1

Литература / References

  1. World Health Organization (WHO). The Use of the WHO-UMC System for Standardised Case Causality As- sessment. WHO Collaborating Centre for International Drug Monitoring (Uppsala Monitoring Centre, UMC), Da- tabase 2000. https://www. who-umc.org/media/2768/ standardised-case-causality-assessment.pdf
  2. Ивашкин В.Т. (ред.). Болезни печени и желчевыводящих путей. М.: Издательский дом «М-Вести», 2002. 416 c. [Ivashkin V.T. (ed.) Diseases of the liver and biliary tract. M.: Publishing house “M-Vesti”, 2002. 416 p. (In Rus.)].
  3. Полунина Т.Е., Маев И.В. Лекарственный гепатит. Consilium medicum. Гастроэнтерология. 2008;1:3–10 [Polunina T.E., Maev I.V. Medicinal hepatitis. Consil- ium medicum. Gastroenterology. 2008;1:3–10 (In Rus.)].
  4. Bahirwani R., Reddy K.R. Drug-induced liver injury due to cancer chemo-therapeutic agents. Semin Liver Dis. 2014;34(2):162–71.
  5. Chalasani N.P., Hayashi P.H., Bonkovsky H.L. et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroen- terol. 2014;109(7):950–66.
  6. Navarro V.J., Barnhart H.X., Bonkovsky H.L. et al. 167 herbal and dietarysupplement induced hepatotoxicity in the US. Gastroenterology. 2012;142(5) (Suppl 1):41.
  7. Rawlins M., Thompson U. Mechanisms of adverse drug reactions. In: Davies D. (ed.) Textbook of adverse drug reactions. N.Y.: Oxford University Press. 1991. P. 18–45.
  8. Reporting adverse drug reactions definitions of terms and criteria for their use. Geneva: CIOMS. 1999. 146 p. 22
  9. Björnsson E.S., Bergmann O.M., Björnsson H.K. et al. Incidence, pre-sentation and outcomes in patients with drug-induced liver injury in the general population of Ice- land. Gastroenterology. 2013;144(7):1419–25.
  10. Leone A., Nie A., Brandon Parker J. et al. Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants. Toxicol Appl Pharmacol. 2014;275(3):189–97.
  11. Sgro C., Clinard F., Ouazir K. et al. Incidence of drug- induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5.
  12. Zimmerman H.J. Drug-induced liver disease. Clin Liver Dis. 2000;4(1):73–96.
  13. Lo Re V. 3rd, Haynes K., Forde K.A. et al. Risk of acute liver failure inpatients with drug-induced liver in- jury: evaluation of Hy’s Law and a new prognostic model. Clin Gastroenterol Hepatol. 2015;13(13):2360–8.
  14. Bunchorntavakul C., Reddy K.R. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013;37(1):3–17.
  15. Ostapowicz G., Fontana R.J., Schiodt F.V. et al. Re- sults of a prospectivestudy of acute liver failure at 17 ter- tiary care centers in the United States. Ann Intern Med. 2002;137(12):947–54.
  16. Ghabril M., Fontana R., Rockey D. et al. Drug-induced liver injury caused by intravenously administered medica- tions: the Drug-Induced Liver Injury Network experience. J Clin Gastroenterol. 2013;47(6):553–8.
  17. Tajiri K., Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008;14(44):6774–85.
  18. Drug-Induced Liver Injury Network. http://www.dilin.org
  19. Burt A.D., Portmann B.C., Ferrell L.D //MacSween’s Pathology of the Liver, Sixth Edition, 2012, P.645–760.
  20. Björnsson E.S., Hoofnagle J.H. Categorization of drugs im- plicated in causing liver injury: critical assessment based upon published case reports. Hepatology. 2016;63(2):590–603.
  21. Ларионова В.Б., Громова Е.Г., Снеговой А.В. Клиниче- ские рекомендации по коррекции гепатотоксичности, ин- дуцированной противоопухолевой химиотерапией. М., 2014 [Larionova V.B., Gromova E.G., Snegovoi A.V. Clinical recommendations for the correction of hepatotox- icity induced by anticancer chemotherapy. Moscow, 2014 (In Rus.)]. http://oncology-association.ru/docs/reco- mend/may2015/09vz-rek.pdf . Maddrey W.C., Boitnott J.K. Drug-induced chronic liver disease. Gastroenterology. 1977;72(6):1348–53.
  22. Aithal G.P., Watkins P.B., Andrade R.J. et al. Review. Case definition andphenotype standardization in drug-in- duced liver injury. Clin Pharmacol Ther. 2011;89(6):806–15.
  23. Sim S.C., Ingelman-Sundberg M. Update on allele no- menclature for humancytochromes P450 and the human cy- tochrome P450 allele (CYP-allele) nomenclature database. Methods Mol Biol. 2013;987:251–9.
  24. Bénichou C. Criteria of drug-induced liver disorders. Re- port of an international consensus meeting. J Hepatol. 1990;11(2):272–6.
  25. Guengerich F.P. Common and uncommon cytochrome P450 reactions relatedto metabolism and chemical toxic- ity. Chem Res Toxicol. 2001;14(6):611–50.
  26. Huang Y.S., Chern H.D., Su W.J. et al. Cytochrome P450 2E1 genotype andthe susceptibility to antituberculosis drug-induced hepatitis. Hepatology. 2003;37(4):924–30.
  27. Delemos A.S., Foureau D.M., Jacobs C. et al. Drug-in- duced liver injurywith autoimmune features. Semin Liver Dis. 2014;34(2):194–204.
  28. Ortega-Alonso A., Stephens C., Lucena M.I., An- drade R.J. Case character-ization, clinical features and risk factors in drug-induced liver injury. Int Mol Sci. 2016;17(5):714.
  29. Andrade R.J., Robles M., Ulzurrun E., Lucena M.I. Drug-induced liverinjury: insights from genetic studies. Pharmacogenomics. 2009;10(9):1467–87.
  30. Aithal G.P., Nicoletti P., Björnsson E. et al. HLA- A*33:01 is strongly asso-ciated with drug-induced liver in- jury (DILI) due to terbinafine and several other unrelated compounds. Hepatology. 2015;65(Suppl 1):325A–6A.
  31. Alfirevic A., Gonzalez-Galarza F., Bell C. et al. In silico analysis of HLAassociations with drug-induced liver in- jury: use of a HLA-genotyped DNA archive from healthy volunteers. Genome Med. 2012;4(6):51.
  32. Daly A.K., Donaldson P.T., Bhatnagar P. et al. HLA-B*5701 genotype is amajor determinant of drug- induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816–9.
  33. Lucena M.I., Molokhia M., Shen Y. et al. Susceptibil- ity to amoxicillin-clavulanate-induced liver injury is influ- enced by multiple HLA class I and II alleles. Gastroenter- ology. 2011;141(1):338–47.
  34. Schaid D.J., Spraggs C.F., McDonnell S.K. et al. Pro- spective validation ofHLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Oncol. 2014;32(22):2296–303.
  35. Singer J.B., Lewitzky S., Leroy E. et al. A genome-wide study identifiesHLA alleles associated with lumiracoxib- related liver injury. Nat Genet. 2010;42(8):711–4.
  36. Chen M., Suzuki A., Borlak J. et al. Drug-induced liver injury: interactions between drug properties and host fac- tors. J Hepatol. 2015;63(2):503–14.
  37. Stephens C., Andrade R.J., Lucena M.I. Mechanisms of drug-inducedliver injury. Curr Opin Allergy Clin Immu- nol. 2014;14(4):286–92.
  38. Dara L., Liu Z., Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016;36(2):158–65.
  39. Uetrecht J.P. New concepts in immunology relevant to idiosyncratic drugreactions: the “danger hypoth- esis” and innate immune system. Chem Res Toxicol. 1999;12(5):387–95.
  40. Lancaster E.M., Hiatt J.R., Zarrinpar A. Acetami- nophen hepatotoxicity: anupdated review. Arch Toxicol. 2015;89(2):193–9.
  41. Chen M., Borlak J., Tong W. High lipophilicity and high daily dose oforal medications are associated with sig- nificant risk for drug-induced liver injury. Hepatology. 2013;58(1):388–96.
  42. Wilke R.A., Lin D.W., Roden D.M. et al. Identify- ing genetic risk factors forserious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 2007;6(11):904–16.
  43. Lucena M.I., Andrade R.J., Kaplowitz N. et al.; Span- ish Group for the Study of Drug-Induced Liver Disease. Phenotypic characterization of idiosyncraticdrug-induced liver injury: The influence of age and sex. Hepatology. 2009;49(6):2001–9.
  44. Heubi J.E., Partin J.C., Partin J.S., Schubert W.K. Reye’s syndrome: Current concepts. Hepatology. 1987;7(1):155–64.
  45. Fountain F.F., Tolley E., Chrisman C.R., Self T.H. Iso- niazid hepatotoxicity associated with treatment of latent tuberculosis infection: A 7-year evalu-ation from a public health tuberculosis clinic. Chest. 2005;128(1):116–23.
  46. Lucena M.I., Andrade R.J., Fernandez M.C. et al. De- terminants of the clinical expression of amoxicillin-cla- vulanate hepatotoxicity: a prospective series from Spain. Hepatol. 2006;44(4):850–6.
  47. Andrade R.J., Lucena M.I., Fernandez M.C. et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology. 2005;129(2):512–21.
  48. Reuben A., Koch D.G., Lee W.M.; Group ALFS. Drug- induced acute liver failure: Results of a U. S. multicenter, prospective study. Hepatology. 2010;52(6):2065–76.
  49. Fontana R.J., Hayashi P.H., Gu J. et al.; on behalf of the DILIN Network. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mor- tality within 6 months from onset. Gastroenterology. 2014;147(1):96–108.
  50. Байкова И.Е., Никитин И.Г. Лекарственное поражение печени. РМЖ. 2009;1:4–10 [Baykova I.E., Nikitin I.G. Drug-induced liver injuries. RMJ. 2009;1:4–10 (In Rus.)].
  51. Andrade R.J., Lopez-Ortega S., Lopez-Vega M.C. et al. Idiosyncratic drug hepatotoxicity: a 2008 update. Expert Rev Clin Pharmacol. 2008;1(2):261–76.
  52. Lee W.M., Hynan L.S., Rossaro L. et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterol- ogy. 2009;37(3):856‒64.
  53. Lomtadze N., Kupreishvili L., Salakaia A. et al. Hepa- titis C virus co-infection increases the risk of anti-tuber- culosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS ONE. 2013;8(12):714.
  54. Sulkowski M.S., Thomas D.L., Mehta S.H. et al. Hepa- totoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepa-titis C and B infec- tions. Hepatology. 2002;35(1):182–9.
  55. Abajo F.J. de, Montero D., Madurga M., Garcia Rod- ríguez L.A. Acute andclinically relevant drug-induced liv- er injury: a population based case-control study. Br J Clin Pharmacol. 2004;58(1):71–80.
  56. Li J., Qiu X., Guo W. et al. Prospective analysis of tio- pronin in prevention ofsorafenib and antiviral therapy in- ducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma. Med Oncol. 2015;32(10):238.
  57. Lucena M.I., García-Martín E., Andrade R.J. et al. Mi- tochondrial superoxide dismutase and glutathione peroxi- dase in idiosyncratic drug-induced liver injury. Hepatol- ogy. 2010;52(1):303–12.
  58. Han D., Dara L., Win S. et al. Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends Pharmacol Sci. 2013;34(4):243–53.
  59. Morgan R.E., Trauner M., van Staden C.J. et al. Inter- ference with bile salt export pump function is a suscepti- bility factor for human liver injury in drug development. Toxicol Sci. 2010;118(2):485–500.
  60. Aleo M.D., Luo Y., Swiss R. et al. Human drug-induced liver injury severity is highly associated with dual inhibi- tion of liver mitochondrial function and bile salt export pump. Hepatology. 2014;60(3):1015–22.
  61. Geier A., Wagner M., Dietrich C.G., Trauner M. Princi- ples of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regen-eration. Biochim Biophys Acta. 2007;1773(3):283–308.
  62. Bénichou C., Danan G., Flahault A. Causality assess- ment of adverse reactions to drugs: II. An original mod- el for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331–6.
  63. Danan G., Benichou C.J. Causality assessment of ad- verse reactions to drugs: I. A novel method based on the conclusions of international consensus meetings: Appli- cation to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–30.
  64. Danan G., Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1):14.
  65. Danan G.; Hepatology Working Group. Causal- ity assessment of drug-induced liver injury. J Hepatol. 1988;7(1):132–36.
  66. Maria V.A., Victorino R.M. Development and validation of a clinical scale for the diagnosis of drug-induced hepati- tis. Hepatology. 1997;26(3):664–9.
  67. Takikawa H., Takamori Y., Kumagi T. et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res. 2003;27(3):192–5.
  68. Fontana R.J., Watkins P.B., Bonkovsky H.L. et al. Rationale, design and conduct of the Drug Induced Liver Injury Network prospective study. Drug Saf. 2009;32(1):55–68.
  69. LiverTox. Clinical and research information on drug-in- duced liver injury. https://livertox.nih.gov
  70. Федеральный закон от 12.04.2010 № 61-ФЗ «Об обраще- нии лекарственных средств» (ред. от 03.07.2016, с изм. и доп., вступ. в силу с 01.01.2017). Российская газета. Федеральный выпуск № 5157(78) [Federal Law passed 12.04.2010 No. 61-FZ “On the Circulation of Medicinal Products” (as amended on 03.07.2016, as amended and added, put into action from 01.01.2017). Russian newspa- per. Federal issue № 5157(78) (In Rus.)].
  71. Fontana R.J. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146(4):914–28.
  72. Björnsson E.S., Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol. 2009;50(3):511–7.
  73. Robles-Diaz M., Lucena M.I., Kaplowitz N. et al.; Spanish DILI Registry; SLatinDILI Network; Safer and Faster Evidence-based Translation Consortium. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver in- jury. Gastroenterology. 2014;147(1):109–18.
  74. Zimmerman H.J. Drug-induced liver disease. In: Hepato- toxicity: the adverse effects of drugs and other chemicals on the liver. N.Y.: Appleton-Century-Crofts, 1978. P. 351–3.
  75. Temple R. Hy’s law: Predicting Serious Hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15(4):241–3.
  76. Kleiner D.E., Chalasani N.P., Lee W.M. et al.; DILIN. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associa- tions. Hepatology. 2014;59(2):661–70.
  77. Mohankumar N., Ranjan P., Kumari A. Drug-induced liver injury: diagnosing (and treating) it early. J Fam Pract. 2015;64(10):634–44.
  78. https://www.fda.gov/downloads/guidances/UCM174090.pdf
  79. Krenzelok E.P. The FDA Acetaminophen Advisory Com- mittee Meeting — what is the future of acetaminophen in the United States: the perspective of a committee member. Clin Toxicol (Phila). 2009;47(8):784–9.
  80. Zhu S.S., Dong Y., Gan Y. et al. Efficacy and safety of ademetionine for treatment of drug-induced liver disease in children. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2010;24(2):136–8.
  81. Russo M.W., Galanko J.A., Shrestha R. et al. Liver transplantation for acute liver failure from drug in- duced liver injury in the United States. Liver Transpl. 2004;10(8):1018–23.
  82. Saliba F., Camus C., Durand F. et al. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med. 2013;159(8):522–31.
  83. Leone A., Nie A., Brandon Parker J. et al. Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxi-cants. Toxicol Appl Pharmacol. 2014;275(3):189–97.
  84. Stine J.G., Lewis J.H. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2016;10(4):517–36.
  85. Leise M.D., Poterucha J.J., Talwalkar J.A. Drug-in- duced liver injury. Mayo Clin Proc. 2014;89(1):95–106.
  86. Woodhead J.L., Howell B.A., Yang Y. et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Phar- macol Exp Ther. 2012;342(2):529–40.
  87. Borraz Y., Fernandez M.C., Garcia-Munos B. et al. Would it be desirable to modify the cut-off point for defi- nition of chronicity in drug-induced liver injury (DILI)? Hepatology. 2010;52:457A.
  88. Russell S. Carnitine as an antidote for acute valproate tox- icity in children. Curr Opin Pediatr. 2007;19(2):206–10.
  89. EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004.
  90. Björnsson E.S. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterology Hepatol. 2015;13(3):602–8.
  91. https://medi.ru/instrukciya/opdivo_13110/
  92. https://www.cancer.gov/about-cancer/causes-prevention
  93. Давыдов М.И. (ред.) Протоколы клинических рекомен- даций поддерживающей терапии в онкологии. Общество специалистов поддерживающей терапии в онкологии (RSASC). 2 изд., перераб. и доп. М.: АБВ-пресс, 2018. 224 с. [Davydov M.I. (ed.) Protocols of clinical recom- mendations of maintenance therapy in oncology. The So- ciety of Supportive care in Oncology (RASSC). 2nd ed., revised and enlarged. Moscow: ABC-press, 2018. 224 p. (In Rus.)].
  94. Конопацкова О.М., Аверьянова С.В. Применение Ремаксо- ла при полихимиотерапии у больных раком молочной желе- зы. Онкология. Журнал им. П.А. Герцена. 2015;4(6):35–7 [Konopatskova O.M. Averyanova S.V. The use of Remaxol in polychemotherapy in patients with breast cancer. P.A. Her- zen Journal of Oncology. 2015;4(6):35–7 (In Rus.)].
  95. Конопацкова О.М., Аверьянова С.В. Сопроводительная терапия при проведении полихимиотерапии колоректального рака. Онкология. Журнал им. П.А. Герцена. 2016;5(1):42–6 [Konopatskova O.M., Averyanova S.V. Supporting therapy during polychemotherapy of colorectal cancer. P.A. Herzen Journal of Oncology. 2016;5(1):42–6. (In Rus.)].
  96. Матякин Г.Г., Иванов В.М., Иванова О.В., Шей- кин М.М. Токсико-модифицирующее действие ремак- сола при лечении местно-распространенного рака слизи- стой оболочки полости рта. Стоматология. 2013;6:12–5 [Matyakin G.G., Ivanov V.M., Ivanova O.V., Sheikin M.M. Toxico-modifying effect of remaxol in the treatment of localized cancer of the oral mucosa. Stomatol- ogy. 2013;6:12–5 (In Rus.)].
  97. Черенков В.Г., Петров А.Б., Васильева Т.М., Сторо- женков М.М. Возможности «Ремаксола» для профилак- тики токсических гепатитов при химиотерапии онколо- гических больных. Вопросы онкологии. 2013;3:369–74 [Cherenkov V.G., Petrov A.B., Vasilyeva T.M., Storo- zhenkov M.M. Possibilities of “Remaxol” for the preven- tion of toxic hepatitis during chemotherapy of cancer pa- tients. Problems in oncology. 2013;3:369–74 (In Rus.)].
  98. Безбородова О.А., Немцова Е.Р., Александрова Л.Н., Суханов Д.С., Коваленко А.Л., Якубовская Р.И. Оцен- ка детоксицирующего действия препарата «Ремаксол» на экспериментальной модели токсикоза, индуцированного цисплатином. Экспериментальная и клиническая фар- макология. 2011;3:26–31 [Bezborodova O.A., Nemtso- va E.R., Aleksandrova L.N., Sukhanov D.S., Kovalen- ko A.L., Yakubovskaya R.I. Evaluation of the detoxifying effect of the “Remaxol” drug using an experimental model of toxicity induced by cisplatin. Experimental and Clinical Pharmacology. 2011;3:26–31 (In Rus.)].
  99. 100. Бажанова Е.Д., Суханов Д.С., Теплый Д.Л. Пути регу- ляции апоптоза гепатоцитов, вызванного противотубер- кулезными препаратами основного ряда. Бюллетень экс- периментальной биологии и медицины. 2014;11:600–3 [Bazhanova E.D., Sukhanov D.S., Teplyi D.L. Ways of regulating hepatocyte apoptosis caused by main-line anti- tuberculosis drugs. Bulletin of Experimental Biology and Medicine. 2014;11:600–3 (In Rus.)].
  100. 101. Суханов Д.С., Виноградова Т.И., Заболотных Н.В. и др. Сравнительное изучение гепатопротективного дей- ствия ремаксола, реамберина и адеметионина при по- вреждении печени противотуберкулезными препаратами (экспериментальное исследование). Антибиотики и хи- миотерапия. 2011;1–2:12–6 [Sukhanov D.S., Vinogra- dova T.I., Zabolotnykh N.V. et al. Comparative study of the hepatoprotective action of remaxol, reamberin and ademetionine in liver damage with anti-tuberculosis drugs (experimental study). Antibiotics and Chemotherapy. 2011;1–2:12–6 (In Rus.)].
  101. 102. Суханов Д.С., Артюшкова Е.Б., Дудка В.Т., Окови- тый С.В. Эффективность ремаксола и адеметионина при сочетанном экспериментальном поражении печени противотуберкулезными препаратами резервного ряда и алкоголем. Туберкулез и болезни легких. 2014;4:59–62 [Sukhanov D.S., Artyushkova E.B., Dudka V.T., Okov- ity S.V. The effectiveness of remaxol and ademethionine in combined experimental liver injury by reserve anti-tu- berculosis drugs and alcohol. Tuberculosis and Lung Dis- eases. 2014;4:59–62 (In Rus.)].
  102. 103.Суханов Д.С., Иванов А.К., Романцов М.Г., Ковален- ко А.Л. Лечение гепатотоксических осложнений сук- цинатсодержащими препаратами. РМЖ. 2009;6:22–5 [Sukhanov D.S., Ivanov A.K., Romantsov M.G., Kova- lenko A.L. Treatment of hepatotoxic complications with succinate-containing preparations. Russian Medical Jour- nal. 2009;6:22–5 (In Rus.)].
  103. 104. Мордык А.В., Иванова О.Г., Нагибина Л.А. и др. Ле- карственные поражения печени и их лечение в клинике туберкулеза. Туберкулез и болезни легких. 2015;9:47– 52 [Mordyk A.V., Ivanova O.G., Nagibina L.А. et al. Medicinal lesions of the liver and their treatment in the clinic of tuberculosis. Tuberculosis and Lung Disease. 2015;9:47–52 (In Rus.)].
  104. 105. Шевырева Е.В., Иванов А.К., Суханов Д.С., Мурзи- на А.А. Гепатопротективная терапия ремаксолом у боль- ных туберкулезом и ВИЧ-инфекцией в дневном стаци- онаре противотуберкулезного диспансера. Антибиотики и химиотерапия. 2012;57:7–8 [Shevyreva E.V., Ivanov A.K., Sukhanov D.S., Murzina A.A. Hepatoprotective therapy with remaxol in patients with tuberculosis and HIV infection in a day hospital at a tuberculosis dispensary. An- tibiotics and Chemotherapy. 2012;57:7–8 (In Rus.)].
  105. 106. Суханов Д.С., Павлова М.В., Яблонский П.К., Вино- градова Т.И. Сравнительная эффективность клиническо- го применения реамберина, ремаксола и адеметионина у больных туберкулезом органов дыхания с лекарственны- ми поражениями печени. Антибиотики и химиотерапия. 2012;58:1–2 [Sukhanov D.S., Pavlova M.V., Yablon- sky P.K., Vinogradova T.I. Comparative efficacy of clini- cal use of reamberin, remaxol and ademethionine in pa- tients with respiratory tuberculosis with medicinal lesions of the liver. Antibiotics and Chemotherapy. 2012;58:1–2 (In Rus.)].
  106. 107. Михеев Е.Ю., Мищенко С.В., Гилей А.Ю., Гизату- лин Э.Я., Орлов Ю.П. Случай благоприятного исхода острого отравления потенциально смертельными доза- ми парацетамола. Клиническая медицина. 2011;4:67–68 [Mikheev E.Yu., Mishchenko SV, Gily A.Yu., Gizatu- lin E.Ya., Orlov Yu.P. The case of a favorable outcome of acute poisoning with potentially fatal doses of paracetamol. Clinical Medicine. 2011;4:67–68 (In Rus.)].
  107. 108. Оковитый С.В., Шуленин С.Н. Клиническая фармако- логия гепатопротекторов. СПб., 2006. С. 23–4 [Okovity S.V., Shulenin S.N. Clinical pharmacology of hepatopro- tectors. St. Petersburg, 2006. P. 23–24 (In Rus.)].
  108. Santini D., Vincenzi B., Massacesi C., Picardi A., Gen- tilucci U.V., Esposito V. et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy- induced liver injury. Anticancer Res. 2003;23(6D):5173–9.
  109. Vincenzi B., Russo A., Terenzio A., Galvano A., San- tini D., Vorini F. et al. The use of SAMe in chemother- apy-indised liver injury. Clinical Reviews in Oncology/ Hematology. 2018;130:70–7.
  110. Li T.W., Peng H., Yang H., Kurniawidjaja S., Pan- thaki P., Zheng Y. et al. S-Adenosylmethionine and methylthioadenosine inhibit β-catenin signaling by mul- tiple mechanisms in liver and colon cancer. Mol Pharma- col. 2015;87(1):77–86. DOI: 10.1124/mol.114.095679.
  111. 112. Снеговой А.В., Ларионова В.Б., Зейналова П.А. и др. Окончательные результаты проспективной многоцен- тровой программы Р12-717 (применение Гептрала при хронической болезни печени, обусловленной лекарствен- но-индуцированным поражением печени вследствие хи- миотерапии). Вестник РОНЦ им. Н.Н. Блохина РАМН. 2016;2:143–56 [Snegovoi A.V., Larionova V.B., Zey- nalova P.A. et al. Final results of the prospective mul- ticenter P12-717 program (use of Heptral in chronic liver disease caused by drug-induced liver damage due to chemo- therapy). Bulletin of the RNTS named after N.N. Blokhin RAMS. 2016;2:143–56 (In Rus.)].
  112. 113. Снеговой А.В., Громова Е.Г., Ларионова В.Б. Практи- ческие рекомендации по коррекции гепатотоксичности, индуцированной противоопухолевой химиотерапией. Злокачественные опухоли. 2015;4(спецвыпуск):358–68 [Snegovoi A.V., Gromova E.G., Larionova V.B. Practi- cal recommendations for the correction of hepatotoxicity induced by anti-tumor chemotherapy. Malignant tumors. 2015;4(special issue):358–68 (In Rus.)].
  113. Perlamutrov Y., Bakulev A., Korsunskaya I. et al. Ade- metionine in treatment of drug induced liver injury: an observational study in Russian patients, receiving immu- nosuppressive therapy for psoriasis. Int J Pharmac Sc Res. 2014;5(12):1000–7.
  114. Neri S., Signorelli S.S., Ierna D. et al. Role of Ademe- tionine (S-Adenosylmethionine) in Cyclosporin-Induced Cholestasis. Clin Drug Invest. 2002;22(3):191–5.
  115. Li M., Liu G.-T. Inhibition of Fas/FasL mRNA expres- sion and TNF-α release in concanavalin A-induced liver injury in mice by bicyclol. World Journal of Gastroen- terology. 2004;10(12):1775–9. DOI: 10.3748/wjg.v10. i12.1775
  116. Liu G.-T., Li Y., Wei H.-L. et al. Toxicity of novel anti- hepatitis drug bicyclol: A preclinical study. World Journal of Gastroenterology. 2005;11(5):665–71. DOI: 10.3748/ wjg.v11.i5.665
  117. Bao X., Liu G. Bicyclol protects HepG2 cells against D- galactosamine-induced apoptosis through inducing heat shock protein 27 and mitochondria associated path- way. Acta Pharmacologica Sinica. 2010;31(2):219–26. DOI: 10.1038/aps.2009.194
  118. Wang Y., Nie H., Zhao X., Qin Y., Gong X. Bicyclol induces cell cycle arrest and autophagy in HepG2 hu- man hepatocellular carcinoma cells through the PI3K/ AKT and Ras/Raf/MEK/ERK pathways. BMC Cancer. 2016;16:742. DOI: 10.1186/s12885-016-2767-2
  119. https://www.vidal.ru/drugs/bicyclol 44816
  120. Wu N., Wang L., Han Z., Guo Y., Zhu C., Gao Y. et al. A Multicenter and Randomized Controlled Trial of Bicy- clol in the Treatment of Statin-Induced Liver Injury. Med Sci Monit. 2017;23:5760–6. DOI: 10.12659/MSM.904090
  121. Li X., Zhou J., Chen S., Guan M., Wang Y., Zhao L. et al. Role of bicyclol in preventing chemotherapeu- tic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014;42(4):906–14. DOI: 10.1177/0300060514527058
  122. Chu N.H., Li L., Zhang X., Gu J., Du Y.D., Cai C. et al. Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease. J Tuberc Lung Dis. 2015 Apr;19(4):475–80. DOI: 10.5588/ijtld.14.0579
  123. Liu X., Zhao M., Mi J., Chen H., Sheng L., Li Y. Pro- tective Effect of Bicyclol on Anti-Tuberculosis Drug In- duced Liver Injury in Rats. Molecules. 2017;22:524. DOI: 10.3390/molecules22040524
  124. Shang W., Feng Y., Li J., Wang X., Xie H., Feng G. Effect of Bicyclol Tablets on Drug Induced Liver In- juries after Kidney Transplantation. Open Medicine. 2017;12:62–9.
  125. Devarbhavy H. An Update on Drug-induced Liver Injury. J Clin Exp Hepatol. 2012;2(3):247–59.
  126. Yi-Shin Huang. The Therapeutic Efficacy of Ursodeoxy- cholic Acid (UDCA) in Drug-Induced Liver Injury: Re- sults of a Randomized Controlled Trial. https://www. gastrojournal.org/article/S0016-5085(10)63727-4/pdf
  127. Wree A., Dechêne A., Herzer K., Hilgard P., Syn W.K., Gerken G., Canbay A. Steroid and ursodesoxycholic Acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84:54–9.
  128. 129. Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю., Лерман О.В., Невзорова В.А., Резник И.И. и др. Из- учение влияния урсодезоксихолевой кислоты на эффек- тивность и безопасность лечения статинами у больных с заболеваниями печени, желчного пузыря и/или желче- выводящих путей (исследование РАКУРС). Рациональ- ная фармакотерапия в кардиологии. 2014;(10)2:147–52 [Martsevich S.Yu., Kutishenko N.P., Drozdova L.Yu., Lerman O.V., Nevzorova V.A., Reznik I.I. et al. Ef- fect of ursodeoxycholic acid on the efficacy and safety of statin treatment in patients with the diseases of the liver, gallbladder and/or biliary tract (RAKURS study). Ratio- nal Pharmacotherapy in Cardiology. 2014;(10)2:147–52 (In Rus.)].
  129. 130. Ивашкин В.Т., Широкова Е.Н., Маевская М.В. и др. Клинические рекомендации Российской гастроэн- терологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;25(2):41–57 [Ivashkin V.T., Shi- rokova E.N., Mayevskaya M.V. et al. Clinical recom- mendations of the Russian Gastroenterological Association and the Russian Society for the Study of the Liver for the Diagnosis and Treatment of Cholestasis. Russian Jour- nal of Gastroenterology, Hepatology and Coloproctology. 2015;25(2):41–57 (In Rus.)].
  130. 131. Гундерманн К.Й. Новейшие данные о механизмах дей- ствия и клинической эффективности эссенциальных фосфолипидов. Клинические перспективы гастроэнтеро- логии и гепатологии. 2002;2:3–8 [Gunderman K.J. The latest data on the mechanisms of action and clinical ef- ficacy of essential phospholipids. Сlinical perspectives of gastroenterology and hepatology. 2002;2:3–8 (In Rus.)].
  131. 132.Ивашкин В.Т., Федосьина Е.А., Маевская М.В. и др. Сфера применения эссенциальных фосфолипидов. Кли- нические перспективы гастроэнтерологии и гепатологии. 2008;5:3–8 [Ivashkin V.T., Fedosina E.A., Mayevskaya
  132. M.V. et al. Scope of application of essential phospholip- ids. Сlinical perspectives of gastroenterology and hepatol- ogy. 2008;5:3–8 (In Rus.)].
  133. 133.Гуревич К.Г. Возможности применения эссенциале при ле- карственных поражениях печени. Фарматека. 2007;2:46–8 [Gurevich K.G. Possibilities of the use of Essentiale in drug- induced liver injuries. Farmateka. 2007;2:46–8 (In Rus.)].
  134. 134.Скрипник И.Н. Эссенциальные фосфолипиды в лечении и профилактике медикаментозных поражений печени. Сучасна гастроентерологiя. 2009;4:22–31 [Skrypnyk I.N. Essential phospholipids in the treatment and prevention of drug-induced liver injuries. Modern gastroenterology. 2009;4:22–31 (In Rus.)].
  135. 135.Пальгова Л.К., Борисова И.В., Жесткова Н.В., Та- расова М.А. Применение эссенциальных фосфолипи- дов в лечении лекарственных поражений печени при беременности. Журнал акушерства и женских болез- ней. 2017;LXVI(2):14–23 [Palgova L.K, Borisova I.V., Zhestkova N.V., Tarasova M.A. The use of essential phospholipids in the treatment of drug-induced liver in- juries during pregnancy. Journal of Obstetrics and Female Diseases. 2017;LXVI(2):14–23 (In Rus.)].
  136. Chen H., Lin F., Yang Z.H. et al. Protective effects of silybin ursodeoxycholic acid evaporated co-precipitate on CCl4-induced acute liver injury in mice. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2016;32(1):38–40, 45.
  137. Jahan S., Khan M., Imran S., Sair M. The hepatoprotec- tive role of Silymarin in isoniazid induced liver damage of rabbits. J Pak Med Assoc. 2015;65(6):620–2.
  138. Zhu S.S., Dong Y., Gan Y. et al. Efficacy and safety of ademetionine for treatment of drug-induced liver disease in children. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2010;24(2):136–8.
  139. Chalasani N., Fontana R.J., Bonkovsky H.L. et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–34.

Для продолжения работы требуется вход / регистрация